You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlupentixol
Accession NumberDB00875  (APRD00388)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionFlupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. It is not approved in the United States.
Structure
Thumb
Synonyms
Flupenthixol
Flupenthixole
Flupentixol
Flupentixol
Flupentixol
Flupentixolo
Flupentixolum
External Identifiers
  • FX 703
  • LC 44
  • LU 5-110
  • N 7009
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluanxol 0.5mg - TabTablet0.5 mgOralLundbeck Canada Inc1995-12-31Not applicableCanada
Fluanxol 3mg - TabTablet3 mgOralLundbeck Canada Inc1995-12-31Not applicableCanada
Fluanxol Depot 10%- Liq Im 100mg/mlSolution100 mgIntramuscularLundbeck Canada Inc1995-12-31Not applicableCanada
Fluanxol Depot 2% -liq Im 20mg/mlSolution20 mgIntramuscularLundbeck Canada Inc1995-12-31Not applicableCanada
Fluanxol Depot Inj 100mg/mlLiquid100 mgIntramuscularMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1981-12-311996-09-09Canada
Fluanxol Depot Inj 20mg/mlLiquid20 mgIntramuscularMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1981-12-311996-09-09Canada
Fluanxol Tab 0.5mgTablet0.5 mgOralMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1986-12-311996-09-09Canada
Fluanxol Tab 3mgTablet3 mgOralMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1986-12-311996-09-09Canada
Flupentixol Decanoate Injection BPSolution100 mgIntramuscularSandoz Canada Incorporated2009-08-27Not applicableCanada
Flupentixol Decanoate Injection BPSolution20 mgIntramuscularSandoz Canada IncorporatedNot applicableNot applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DepixolLundbeck A/S
FluanxolLundbeck A/S
JexitJohnson
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Flupentixol decanoate
ThumbNot applicableDBSALT000928
Flupentixol dihydrochloride
ThumbNot applicableDBSALT000929
Categories
UNIIFA0UYH6QUO
CAS number2709-56-0
WeightAverage: 436.533
Monoisotopic: 436.179618801
Chemical FormulaC23H27F3N2OS
InChI KeyDTTVNHWDONBIKE-DVZOWYKESA-N
InChI
InChI=1S/C23H27F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,20,22,29H,3,9-15H2/b18-5-
IUPAC Name
2-(4-{3-[2-(trifluoromethyl)-9,9a-dihydro-4aH-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol
SMILES
[H]C(CCN1CCN(CCO)CC1)=C1C2C=C(C=CC2SC2=C1C=CC=C2)C(F)(F)F
Pharmacology
IndicationFor use in the treatment of schizophrenia and depression
Structured Indications
PharmacodynamicsFlupenthixol is an anxiolytic, antidepressive agent and a mood stabilizer. It inhibits the central monoamine receptors, particularly the dopamine D1 and D2 receptors. Therefore, it increases the amount of serotonin and noradrenaline that control mood and thinking, and improves mood.
Mechanism of actionFlupenthixol is a thioxanthene antipsychotic. The mechanism of action of Flupenthixol is not completely understood. Flupenthixol is a powerful antagonist of both D1 and D2 dopamine receptors, and an alpha-adrenergic receptor antagonist. It's antipsychotic activity is thought to be related to blocks postsynaptic dopamine receptors in the CNS.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
D(1A) dopamine receptorProteinyes
antagonist
HumanP21728 details
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Related Articles
AbsorptionFairly slow and incomplete after oral administration
Volume of distributionNot Available
Protein bindingHighly bound to plasma proteins (>95%)
Metabolism

Mainly hepatic

Route of eliminationNot Available
Half life19 to 39 hours
ClearanceNot Available
ToxicityLD50=300 mk/kg (Oral in mice); LD50=791 mg/kg (Oral in rats); LD50=87 mk/kg (IV in mice); LD50=37 mg/kg (IV in rats)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Flupentixol is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineFlupentixol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineFlupentixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineFlupentixol may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineFlupentixol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Flupentixol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Flupentixol.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Flupentixol.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Flupentixol is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Flupentixol.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Flupentixol.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Flupentixol.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Flupentixol.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Flupentixol.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flupentixol.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Flupentixol.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Flupentixol.Approved, Investigational
AmiodaroneFlupentixol may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Flupentixol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Flupentixol.Approved
AmperozideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amperozide.Experimental
AmphetamineFlupentixol may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideAnagrelide may increase the QTc-prolonging activities of Flupentixol.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Flupentixol.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
Arsenic trioxideFlupentixol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherFlupentixol may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Articaine.Approved
AsenapineFlupentixol may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Flupentixol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Flupentixol.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Flupentixol.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Azaperone.Vet Approved
AzelastineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Flupentixol.Approved
BaclofenThe risk or severity of adverse effects can be increased when Flupentixol is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Barbital.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Flupentixol.Approved
BenperidolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Benzocaine.Approved
BenzphetamineFlupentixol may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Flupentixol is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Flupentixol.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Flupentixol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Flupentixol.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flupentixol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flupentixol.Approved, Investigational
BuprenorphineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Flupentixol.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flupentixol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flupentixol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flupentixol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Flupentixol.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Flupentixol.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Flupentixol.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Flupentixol.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Flupentixol.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Flupentixol.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Flupentixol.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carisoprodol.Approved
CeritinibCeritinib may increase the QTc-prolonging activities of Flupentixol.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Flupentixol.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flupentixol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chloroprocaine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorphenamine.Approved
ChlorphentermineFlupentixol may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorzoxazone.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Flupentixol.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flupentixol.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Flupentixol.Approved
CitalopramCitalopram may increase the QTc-prolonging activities of Flupentixol.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Flupentixol.Approved
ClemastineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Flupentixol.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Flupentixol.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Flupentixol.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Flupentixol.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flupentixol.Approved, Illicit
ClozapineClozapine may increase the QTc-prolonging activities of Flupentixol.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Flupentixol.Approved
CocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flupentixol.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Flupentixol.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Flupentixol.Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Flupentixol.Approved
CyclizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclobenzaprine.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Flupentixol.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flupentixol.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Flupentixol.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Flupentixol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Flupentixol.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flupentixol.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dapoxetine.Investigational
DasatinibDasatinib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Flupentixol.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Flupentixol.Approved
DegarelixDegarelix may increase the QTc-prolonging activities of Flupentixol.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Flupentixol is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Flupentixol.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Flupentixol.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Flupentixol.Approved
DetomidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Flupentixol.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flupentixol.Approved, Vet Approved
DextroamphetamineFlupentixol may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Flupentixol.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flupentixol.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Flupentixol.Approved, Illicit, Vet Approved
DiethylpropionFlupentixol may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Flupentixol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Flupentixol.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Flupentixol.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Flupentixol.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Flupentixol.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Flupentixol.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Flupentixol.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Flupentixol.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Flupentixol.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Flupentixol.Approved, Investigational
DofetilideDofetilide may increase the QTc-prolonging activities of Flupentixol.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Flupentixol.Approved
DomperidoneFlupentixol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Doramectin.Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Flupentixol.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Flupentixol.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Flupentixol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Illicit
DronedaroneFlupentixol may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Flupentixol.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flupentixol.Approved
EcgonineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Flupentixol is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Flupentixol.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Flupentixol is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Flupentixol.Approved, Investigational
EliglustatFlupentixol may increase the QTc-prolonging activities of Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Flupentixol.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Entacapone.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Flupentixol.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Flupentixol.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Flupentixol.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Flupentixol.Approved
EribulinEribulin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Flupentixol.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
EscitalopramFlupentixol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Flupentixol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Flupentixol.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Flupentixol.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flupentixol.Approved
EthanolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flupentixol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Flupentixol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Flupentixol.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Flupentixol.Approved
EtorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Flupentixol.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Flupentixol.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Flupentixol.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Flupentixol.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Flupentixol.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flupentixol.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Flupentixol.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Flupentixol.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Flupentixol.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flibanserin.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Flupentixol.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flunitrazepam.Approved, Illicit
FluoxetineFluoxetine may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flupentixol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flupentixol.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Flupentixol.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Flupentixol.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Flupentixol.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Flupentixol.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Flupentixol is combined with gabapentin enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Flupentixol.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Flupentixol.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Flupentixol.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Flupentixol.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Glutethimide.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Flupentixol.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Flupentixol.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Flupentixol.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Flupentixol.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Flupentixol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Flupentixol.Approved
HydrocodoneFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Flupentixol.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flupentixol.Approved, Illicit
Hydroxyamphetamine hydrobromideFlupentixol may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Flupentixol.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Flupentixol.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Flupentixol.Approved
IloperidoneFlupentixol may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Flupentixol.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Flupentixol.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Flupentixol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Flupentixol.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Flupentixol.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Flupentixol.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Flupentixol.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Flupentixol.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Flupentixol.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Flupentixol.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Flupentixol.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Flupentixol.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketobemidone.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Flupentixol.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Flupentixol.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Flupentixol.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Flupentixol.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Flupentixol.Approved
LenvatinibLenvatinib may increase the QTc-prolonging activities of Flupentixol.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Flupentixol.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Flupentixol.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flupentixol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Flupentixol.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Flupentixol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Flupentixol.Approved, Investigational
LisdexamfetamineFlupentixol may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Flupentixol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Flupentixol.Approved
LopinavirFlupentixol may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flupentixol.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Flupentixol.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Flupentixol.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flupentixol.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Flupentixol is combined with Lu AA21004.Investigational
LumefantrineFlupentixol may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Flupentixol.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Flupentixol.Approved
MeclizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Flupentixol.Approved
MelatoninThe risk or severity of adverse effects can be increased when Flupentixol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Melperone.Approved
MephedroneFlupentixol may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineFlupentixol may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flupentixol.Approved, Illicit
MequitazineFlupentixol may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Metaxalone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Flupentixol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineFlupentixol may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Flupentixol.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Flupentixol.Approved
MethotrimeprazineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flupentixol.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Flupentixol.Approved, Vet Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Flupentixol.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Flupentixol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Flupentixol.Approved
MetyrosineFlupentixol may increase the sedative activities of Metyrosine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Flupentixol.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Flupentixol.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Flupentixol.Approved
MirtazapineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Flupentixol.Approved, Investigational
MMDAFlupentixol may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Flupentixol.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Flupentixol.Approved
MolindoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Flupentixol.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Flupentixol.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Flupentixol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flupentixol.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Flupentixol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Flupentixol.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Flupentixol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Flupentixol.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Flupentixol.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Flupentixol.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Flupentixol.Approved
NilotinibFlupentixol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Flupentixol.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Flupentixol.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Flupentixol.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Flupentixol.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Flupentixol.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Flupentixol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Flupentixol.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Flupentixol.Approved
OpiumThe risk or severity of adverse effects can be increased when Flupentixol is combined with Opium.Approved, Illicit
OrphenadrineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Flupentixol is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Flupentixol.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flupentixol.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flupentixol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Flupentixol.Approved, Vet Approved
PaliperidoneFlupentixol may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
ParaldehydeFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Flupentixol.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Flupentixol.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Flupentixol.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flupentixol.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Flupentixol.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved
PerazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Flupentixol.Approved
PerospironeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flupentixol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flupentixol.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Flupentixol.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Flupentixol.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Phenoxyethanol.Approved
PhentermineFlupentixol may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Flupentixol.Approved, Vet Approved
PimozideFlupentixol may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Flupentixol.Approved
PizotifenThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Flupentixol.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Flupentixol.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Vet Approved
PramipexoleFlupentixol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Flupentixol.Approved
PrazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Flupentixol.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Flupentixol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Flupentixol.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flupentixol.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Flupentixol.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Flupentixol.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Primidone.Approved, Vet Approved
ProcainamideFlupentixol may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Flupentixol.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Flupentixol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flupentixol.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Flupentixol.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Flupentixol.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Flupentixol.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flupentixol.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Flupentixol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Flupentixol.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Flupentixol.Approved
PSD502The risk or severity of adverse effects can be increased when Flupentixol is combined with PSD502.Investigational
PseudoephedrineFlupentixol may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Quazepam.Approved, Illicit
QuetiapineFlupentixol may increase the QTc-prolonging activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Flupentixol.Approved
QuinidineFlupentixol may increase the QTc-prolonging activities of Quinidine.Approved
QuinineQuinine may increase the QTc-prolonging activities of Flupentixol.Approved
RacloprideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Flupentixol.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Flupentixol.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Flupentixol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Flupentixol is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flupentixol.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Flupentixol.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Flupentixol.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Flupentixol.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Flupentixol.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ritanserin.Investigational
RitobegronFlupentixol may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Flupentixol.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Flupentixol.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Flupentixol.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Romifidine.Vet Approved
RopiniroleFlupentixol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flupentixol.Approved
RotigotineFlupentixol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flupentixol.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Flupentixol is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Flupentixol is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Flupentixol.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Flupentixol.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flupentixol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Flupentixol.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Flupentixol.Approved
SertindoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Flupentixol.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Flupentixol.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Flupentixol.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Flupentixol.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Flupentixol.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Flupentixol.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Flupentixol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Flupentixol.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Flupentixol.Experimental
StiripentolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flupentixol.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Flupentixol.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Flupentixol.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
SuvorexantFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Flupentixol.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Flupentixol.Approved
TandospironeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Flupentixol.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Flupentixol.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Flupentixol.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Flupentixol.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Flupentixol.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Flupentixol.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flupentixol.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Flupentixol.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Flupentixol.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Flupentixol.Approved
TetracaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetrodotoxin.Investigational
ThalidomideFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Flupentixol.Approved, Vet Approved
ThioridazineThioridazine may increase the QTc-prolonging activities of Flupentixol.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Flupentixol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Flupentixol.Approved
TiletamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Flupentixol.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Flupentixol.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Flupentixol.Approved
TopiramateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Flupentixol.Approved, Investigational
ToremifeneToremifene may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flupentixol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flupentixol.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Flupentixol.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flupentixol.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flupentixol.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Flupentixol.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Flupentixol.Approved, Vet Approved
Uc1010The risk or severity of adverse effects can be increased when Flupentixol is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Flupentixol.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Flupentixol.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Flupentixol.Approved, Investigational
VandetanibFlupentixol may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Flupentixol.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Flupentixol.Approved
VemurafenibFlupentixol may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Flupentixol.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Flupentixol.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Flupentixol.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Flupentixol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Flupentixol.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Flupentixol.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Flupentixol.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Flupentixol.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Flupentixol.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Flupentixol.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Flupentixol.Approved, Investigational
ZolpidemFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zotepine.Approved
ZuclopenthixolFlupentixol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.
References
Synthesis Reference

Smith Kline & French Laboratories; British Patent 925,538; May 8, 1963.
Craig, P.N. and Zirkle, C.L.; U.S. Patent 3,282,930; November 1, 1966; assigned to Smith Kline & French Laboratories.

General ReferencesNot Available
External Links
ATC CodesN05AF01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9825
Blood Brain Barrier+0.9778
Caco-2 permeable-0.5438
P-glycoprotein substrateSubstrate0.8762
P-glycoprotein inhibitor IInhibitor0.92
P-glycoprotein inhibitor IIInhibitor0.859
Renal organic cation transporterInhibitor0.5065
CYP450 2C9 substrateNon-substrate0.8084
CYP450 2D6 substrateSubstrate0.804
CYP450 3A4 substrateNon-substrate0.6921
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.5657
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7748
Ames testNon AMES toxic0.828
CarcinogenicityNon-carcinogens0.8985
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8385 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6624
hERG inhibition (predictor II)Inhibitor0.7962
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral0.5 mg
TabletOral3 mg
SolutionIntramuscular100 mg
SolutionIntramuscular20 mg
LiquidIntramuscular100 mg
LiquidIntramuscular20 mg
Prices
Unit descriptionCostUnit
Fluanxol Depot 100 mg/ml39.79USD ml
Fluanxol Depot 20 mg/ml7.96USD ml
Fluanxol 3 mg Tablet0.59USD tablet
Fluanxol 0.5 mg Tablet0.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility0.000346 mg/mlNot Available
logP4.51HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.003 mg/mLALOGPS
logP4.12ALOGPS
logP3.54ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.51ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.71 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity120.93 m3·mol-1ChemAxon
Polarizability45.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiopyrans
Sub Class1-benzothiopyrans
Direct ParentThioxanthenes
Alternative Parents
Substituents
  • Thioxanthene
  • Thiochromane
  • Alkylarylthioether
  • N-alkylpiperazine
  • Benzenoid
  • Thiopyran
  • Piperazine
  • 1,4-diazinane
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Thioether
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  3. Ogren SO, Hall H, Kohler C, Magnusson O, Lindbom LO, Angeby K, Florvall L: Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol. 1984 Jul 20;102(3-4):459-74. [PubMed:6149133 ]
  4. Arnt J: Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol. 1995 Sep 5;283(1-3):55-62. [PubMed:7498321 ]
  5. Huettl P, Gerhardt GA, Browning MD, Masserano JM: Effects of dopamine receptor agonists and antagonists on catecholamine release in bovine chromaffin cells. J Pharmacol Exp Ther. 1991 May;257(2):567-74. [PubMed:1674528 ]
  6. Nilsson CL, Ekman A, Hellstrand M, Eriksson E: Inverse agonism at dopamine D2 receptors. Haloperidol-induced prolactin release from GH4C1 cells transfected with the human D2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine. Neuropsychopharmacology. 1996 Jul;15(1):53-61. [PubMed:8797192 ]
  7. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H: Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17. [PubMed:17111172 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H: Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17. [PubMed:17111172 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. [PubMed:10531405 ]
  4. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H: Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17. [PubMed:17111172 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Pyridoxal phosphate binding
Specific Function:
Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine.
Gene Name:
DDC
Uniprot ID:
P20711
Molecular Weight:
53925.815 Da
References
  1. Zhu MY, Juorio AV, Paterson IA, Boulton AA: Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: effects of dopamine receptor agonists and antagonists. Br J Pharmacol. 1994 May;112(1):23-30. [PubMed:7913379 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6. [PubMed:8094615 ]
  2. Dey S, Hafkemeyer P, Pastan I, Gottesman MM: A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. Biochemistry. 1999 May 18;38(20):6630-9. [PubMed:10350482 ]
  3. Hafkemeyer P, Licht T, Pastan I, Gottesman MM: Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers. Hum Gene Ther. 2000 Mar 1;11(4):555-65. [PubMed:10724034 ]
  4. Yang JM, Vassil A, Hait WN: Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells. Biochem Pharmacol. 2002 Mar 1;63(5):959-66. [PubMed:11911848 ]
  5. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN: Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 1990 Mar 15;50(6):1748-56. [PubMed:1968358 ]
  6. Ford JM, Yang JM, Hait WN: Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res. 1991 Jan 1;51(1):67-72. [PubMed:1988108 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23